News
-
Sarcoma impacts childhood cancers
Tuesday | Jun 27 2023WITH Sarcoma Awareness Month in Jul, the Australia and New Zealand Sarcoma Association (ANZSA) is highlighting the importance of ongoing research into rare and complex cancers to increase survival rates, as sarcoma accounts for 20% of cancers diagnosed in childhood.
-
IPO in the wings
Tuesday | Jun 27 2023GALDERMA today announced a private placement of approximately US$1 billion (A$1.5 billion) for newly issued shares, from a group consisting of current shareholders, new investors, as well as management.
-
NDIS wage theft
Tuesday | Jun 27 2023THE Australian Services Union NSW & ACT wants the Govt to urgently stamp out rampant wage theft of disability support workers as it investigates more than 30 providers in NSW alone, and has referred two providers to the NDIS commission.
-
Medcan’s access program milestone
Tuesday | Jun 27 2023MORE than 5,000 patients have benefitted from subsidised access to plant-based treatments since Medcan's Compassionate Access Program (CAP), Cann I Help, began.
-
Co-design plan
Tuesday | Jun 27 2023THE LGBTIQA Health and Wellbeing 10 Year National Action Plan Expert Advisory Group held its first meeting yesterday, to co-design Australia's first national plan alongside communities, focused specifically on improving the health and wellbeing of LGBTIQA people.
-
-
First stage of meds on 60DD out now
Monday | Jun 26 2023THE list of medicines in stage one of the 60-DD policy is now confirmed, with the legislative instrument to enable the policy change registered on the Federal Register of Legislation, ahead of being tabled in the Senate next month, the Federal Dept of Health has confirmed.
-
PATY NSW finalists shine
Monday | Jun 26 2023PHARMACY assistant Morgan Burnside (pictured left) from Priceline Pharmacy Beecroft in Sydney has been chosen to represent New South Wales at the national finals of the 2023 Pharmacy Guild of Australia/Maxigesic Pharmacy Assistant of the Year Award (PATY).
-
Weight loss drug
Monday | Jun 26 2023DURING a mid-stage trial, Eli Lilly's experimental pill orforglipron has led to 14.7% weight loss after 36 weeks, for people who were obese or overweight, setting a marker in the race to develop effective oral obesity drugs, said researchers last week in Reuters.
-
Opioid guidelines
Monday | Jun 26 2023NEW clinical guidelines have been developed by Australian researchers to support medical colleagues in reducing opioid use in their patients.
